Clinical Trials Logo

Amyotrophic Lateral Sclerosis clinical trials

View clinical trials related to Amyotrophic Lateral Sclerosis.

Filter by:

NCT ID: NCT05218668 Active, not recruiting - Clinical trials for Amyotrophic Lateral Sclerosis

Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL)

REAL
Start date: December 22, 2021
Phase: Phase 2
Study type: Interventional

A Phase 2a Open-Label Preliminary Safety, Efficacy, and Biomarker Study of WP-0512 in Patients with Amyotrophic Lateral Sclerosis (ALS)

NCT ID: NCT05178810 Active, not recruiting - Clinical trials for Amyotrophic Lateral Sclerosis

Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With Amyotrophic Lateral Sclerosis

ADORE
Start date: October 18, 2021
Phase: Phase 3
Study type: Interventional

Multicenter, multinational, double-blind, randomized (2:1), placebo-controlled Phase III study to investigate the efficacy and safety of 100 mg FAB122 once daily as oral formulation in ALS patients.

NCT ID: NCT05163886 Active, not recruiting - Clinical trials for Amyotrophic Lateral Sclerosis

Study of Safety, Tolerability, and Biological Activity of LAM-002A in C9ORF72-Associated Amyotrophic Lateral Sclerosis

Start date: December 23, 2021
Phase: Phase 2
Study type: Interventional

This is a clinical trial to evaluate the safety, tolerability, and biological effect of LAM-002A in adults with C9ORF72-associated ALS (C9ALS).

NCT ID: NCT05035823 Active, not recruiting - Clinical trials for Spinal Cord Injuries

COMMAND Early Feasibility Study: Implantable BCI to Control a Digital Device for People With Paralysis

Start date: April 27, 2022
Phase: N/A
Study type: Interventional

The Synchron motor neuroprosthesis (MNP) is intended to be used in subjects with severe motor impairment, unresponsive to medical or rehabilitative therapy and a persistent functioning motor cortex. The purpose of this research is to evaluate safety and feasibility. The MNP is a type of implantable brain computer interface which bypasses dysfunctional motor neurons. The device is designed to restore the transmission of neural signal from the cerebral cortex utilized for neuromuscular control of digital devices, resulting in a successful execution of non-mechanical digital commands.

NCT ID: NCT05021536 Active, not recruiting - Clinical trials for Amyotrophic Lateral Sclerosis

Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment

Phoenix
Start date: October 28, 2021
Phase: Phase 3
Study type: Interventional

The Phoenix Trial is a randomized double blind placebo controlled Phase III trial to evaluate the safety and efficacy of AMX0035 for treatment of ALS

NCT ID: NCT05006352 Active, not recruiting - Clinical trials for Amyotrophic Lateral Sclerosis

A Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants With Amyotrophic Lateral Sclerosis

Start date: August 11, 2021
Phase: Phase 1
Study type: Interventional

This is a Phase 1b, multicenter, randomized, placebo-controlled, double-blind study of 28 days, followed by an 18-month open-label extension, designed to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of DNL343 in participants with amyotrophic lateral sclerosis (ALS)

NCT ID: NCT04997954 Active, not recruiting - Clinical trials for Amyotrophic Lateral Sclerosis

EMERALD TRIAL Open Label Extension Study

EMERALD-OLE
Start date: May 17, 2021
Phase: Phase 4
Study type: Interventional

EMERALD OLE trial is an open-label extension of the EMERALD trial. Long term tolerability and safety of the MediCabilis CBD oil has not been extensively studied. EMERALD OLE aims to establish data on the prolonged used of the study drug product. All participants who completed the EMERALD trial will be offered to enter EMERALD OLE. Participants will be taking the active drug MediCabilis CBD oil for 6 months.

NCT ID: NCT04993755 Active, not recruiting - Clinical trials for Amyotrophic Lateral Sclerosis

A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD

Start date: October 1, 2021
Phase: Phase 2
Study type: Interventional

This is a Phase 2a study to assess the the safety and tolerability of TPN-101 in patients with Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD) Associated with Hexanucleotide Repeat Expansion in the C9orf72 gene (C9ORF72 ALS/FTD).

NCT ID: NCT04960540 Active, not recruiting - Clinical trials for Amyotrophic Lateral Sclerosis

Multimodal Brain Imaging Study

Start date: August 1, 2019
Phase:
Study type: Observational

To explain the key brain network nodes and their brain mechanisms of ALS language cognitive impairment and decline, reveal the neural mechanism of the association between ALS language cognitive impairment and motor executive function, and provide potential early diagnostic markers and targeted therapeutic targets for ALS language cognitive impairment.

NCT ID: NCT04948645 Active, not recruiting - Clinical trials for Amyotrophic Lateral Sclerosis

A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Sclerosis

Start date: September 22, 2021
Phase: Phase 1
Study type: Interventional

ABBV-CLS-7262 is an investigational drug being researched for the treatment of Amyotrophic Lateral Sclerosis. This is an up to 156-week, 2-part study. Part 1 will be a 4-week, randomized, double-blind, placebo-controlled study; Part 2 will be up to a 152-week active treatment extension (ATE) during which all subjects will receive ABBV-CLS-7262.